Most patients with a stroke or a transient ischaemic attack require urgent imaging to determine the cause of their symptoms and to guide treatment. Stroke unit care, where available, can facilitate effective use of acute treatments (aspirin and thrombolytic therapy), good multidisciplinary care and early secondary prevention. Implementation of these strategies will have a significant public health impact.
Introduction
In Australia nearly 50 000 people have a stroke each year. A third will die within a year, and a third are left with significant disability. The cost is considerable, whether measured in dollars (5% of the total health budget), social care or by the impact on the families and carers. In the past decade there has been a major change in how stroke is perceived and managed, especially in the acute phase.
Is it a stroke or TIA?
There is now an interesting problem with the nomenclature of stroke and transient ischaemic attack (TIA). By definition (see box) a stroke either leads to death or is still symptomatic 24 hours later, while a TIA resolves to leave no symptoms at 24 hours. These definitions have been essential for epidemiological studies and they are useful to remind clinicians of the differential diagnoses (Table 1) .
Stroke
A clinical syndrome characterised by rapidly developing clinical symptoms and/or signs of focal, and at times global (applied to patients in deep coma and those with subarachnoid haemorrhage), loss of cerebral function, with symptoms lasting more than 24 hours, or leading to death, with no apparent cause other than that of vascular origin. 1
Transient ischaemic attack
A clinical syndrome characterised by an acute loss of focal cerebral or monocular function with symptoms lasting less than 24 hours and which is thought to be due to inadequate cerebral or ocular blood supply as a result of low blood flow, arterial thrombosis or embolism associated with diseases of the arteries, heart or blood. 2 Table 1 Important or common mimics of 'brain attack' The definitions obscure the fact that TIA and ischaemic stroke are actually the same disease. New interventions for some strokes will change the natural history, resulting in a TIA (that is, symptoms resolved by 24 hours). In order to increase the priority given to patients with a suspected stroke it has been suggested that all TIAs and strokes should be called 'acute brain attacks' in the first 24 hours. The final diagnosis of stroke or TIA can be made when the situation is clearer 24 hours later ( Fig. 1 ). 3 No matter what we call the attack, the immediate medical priority is to distinguish attacks that are vascular from the 
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Imaging and pathology of the 'brain attack'
Computed tomography is the most reliable way to identify intracranial haemorrhage as the cause of the 'brain attack'. Blood shows up immediately as a high attenuation lesion on CT and remains visible for the next four to seven days. After this time CT can be unreliable as the blood becomes isodense and then the lesion appears as a low attenuation lesion mimicking an ischaemic area.
Magnetic resonance imaging (MRI) can be used if patients present late, as haemosiderin from a haemorrhagic stroke can be identified by special MRI sequences (such as gradient echo T2 or Flash 2D sequences). However, old blood due to early haemorrhagic transformation of a cerebral infarction will also be identified by this technology.
The key point is that a CT scan is needed as soon as possible to identify the pathology. This is also the most cost-effective strategy. Early pathological diagnosis helps determine the investigations required, for example a carotid duplex scan is not required for a stroke due to primary intracerebral haemorrhage.
A CT scan for a straightforward single TIA is not always required.
If the 'brain attack' has completely resolved within hours, it is a definite TIA; a haemorrhage is very unlikely (less than 1% chance) so the event can be considered ischaemic. While some TIAs are caused by space-occupying lesions, the patients generally have unusual symptoms or multiple attacks.
Who to admit?
Admission to hospital depends on numerous factors: 
General management
There is now overwhelming evidence that care in a stroke unit gives the patient the greatest chance of independent survival.
For every 100 patients treated there will be 40 independent survivors with general non-specialist care and 46 independent survivors in a stroke unit. This gain (six more independent survivors) is two to three times the treatment effect of thrombolysis for acute myocardial infarction. 5 The benefit is due to the cumulative effect of Stroke unit care is standard in many countries (for example Norway), has been mandated in others (for example England and Wales) but has been slow to be developed in Australia. In the absence of a local stroke unit, a rehabilitation unit would be a suitable alternative, once the patient is medically stable.
Medical treatment
Drug treatments include aspirin, thrombolytics and antihypertensives. Anticoagulation, neuroprotection, steroids, mannitol and glycerol have been shown to be ineffective or harmful.
Aspirin
An immediate dose of aspirin for patients with ischaemic stroke is definitely effective, but the effect is modest with only one extra independent survivor per 100 patients treated. 6 However, across Australia, this treatment will prevent 400-500 people from dying or becoming dependent each year. Putting it another way, the benefit of aspirin given for two weeks following an ischaemic stroke is the same as the benefit seen in the subsequent 50 weeks, for routine secondary prevention. This is due to the clustering of recurrent ischaemic stroke in the first few weeks after a stroke or TIA.
Thrombolysis
Recombinant tissue plasminogen activator (rt-PA) has a treatment effect of about 10-15 extra independent survivors per 100 patients treated, despite an additional eight patients with symptomatic intracranial haemorrhage. 7 There is an uncertain effect on overall deaths and treatment is not easy to deliver. In Australia, rt-PA was approved by the Therapeutic Goods Administration in 2003, but only for patients who can be assessed, scanned and treated by experienced stroke teams within three hours of onset. As it can be difficult to meet this deadline, trials are underway to broaden the indications and to evaluate whether treatment given within six hours is safe and effective. The current use of thrombolytic drugs in stroke management is unlikely to have a public health impact, but may help some patients.
Reducing blood pressure
The effect of lowering blood pressure in the acute phase of stroke is uncertain. Some experts prefer to treat patients with sustained very high blood pressure (greater than 180/120), 
Reversal of antithrombotic treatment
Antiplatelet therapy should be stopped, probably indefinitely, if the stroke is due to primary intracerebral haemorrhage.
If anticoagulated patients have a primary intracerebral haemorrhage they need urgent assessment, and haematological advice should be sought to reverse the anticoagulation. It is probably wise not to re-anticoagulate unless the patient has a major ongoing risk of thromboembolism (such as metal prosthetic heart valves).
Surgical treatment
Occasionally surgery is necessary to relieve acute hydrocephalus 
Support for patients and carers
Stroke can be a devastating problem for patients and carers and they need support and information during this critical time. 
Terminal care
About 10% of patients with ischaemic stroke and 50% of those with primary intracerebral haemorrhage die within a month.
Appropriate terminal care is therefore an important part of acute management.
Secondary prevention
The best opportunity to commence secondary prevention is in the acute phase. Stopping smoking should halve the future risk of vascular events. Antithrombotic therapy together with cholesterol and blood pressure lowering are effective for patients with ischaemic stroke. 8, 9, 10 This evidence-based polypharmacy may be a problem for some patients. Secondary prevention for primary intracerebral haemorrhage depends on effective blood pressure lowering. 8 
